Evidence map›Paper›PMID 32301061›Full record

ArticleMolecular and cellular biochemistry2020

Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression.

Moisés Martínez-Castillo, Dorothy Rosique-Oramas, Zaira Medina-Avila, José Luis Pérez-Hernández, Fatima Higuera-De la Tijera, Daniel Santana-Vargas, Eduardo Esteban Montalvo-Jave, Francico Sanchez-Avila, Aldo Torre, David Kershenobich and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Moisés Martínez-CastilloLiver, Pancreas and Motility Laboratory (HIPAM), Unit of Experimental Medicine, School of Medicine, National Autonomous University of Mexico (UNAM), General Hospital of Mexico, Mexico City, Mexico.
Dorothy Rosique-OramasLiver, Pancreas and Motility Laboratory (HIPAM), Unit of Experimental Medicine, School of Medicine, National Autonomous University of Mexico (UNAM), General Hospital of Mexico, Mexico City, Mexico.
Zaira Medina-AvilaLiver, Pancreas and Motility Laboratory (HIPAM), Unit of Experimental Medicine, School of Medicine, National Autonomous University of Mexico (UNAM), General Hospital of Mexico, Mexico City, Mexico.
José Luis Pérez-HernándezGeneral Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, México.
Fatima Higuera-De la TijeraGeneral Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, México.
Daniel Santana-VargasGeneral Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, México.
Eduardo Esteban Montalvo-JaveGeneral Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, México.
Francico Sanchez-AvilaNational Institute of Medical Sciences and Nutrition "Salvador Zubirán", Mexico City, México.
Aldo TorreNational Institute of Medical Sciences and Nutrition "Salvador Zubirán", Mexico City, México.
David KershenobichLiver, Pancreas and Motility Laboratory (HIPAM), Unit of Experimental Medicine, School of Medicine, National Autonomous University of Mexico (UNAM), General Hospital of Mexico, Mexico City, Mexico.
Gabriela Gutierrez-ReyesLiver, Pancreas and Motility Laboratory (HIPAM), Unit of Experimental Medicine, School of Medicine, National Autonomous University of Mexico (UNAM), General Hospital of Mexico, Mexico City, Mexico. gabgurey@yahoo.com.mx.
Hospital General de México · MXInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXUniversidad Nacional Autónoma de México · MX

Funding

Consejo Nacional de Ciencia y Tecnología SALUD-2016-272579
6 · The paper itself

Abstract

Noninvasive methods for liver disease diagnoses offer great advantages over biopsy, but they cannot be utilized in all cases. Therefore, specific indicators for chronic liver disease management are necessary. The aim was to assess the production of insulin-like growth factor-binding proteins (IGFBPs) 1-7 and their correlation with the different stages of fibrosis in chronic hepatitis C (CHC). A prospective, cross-sectional, multicenter study was conducted. CHC patients were categorized by FibroTest® and/or FibroScan®. Serum concentrations of IGFBPs 1-7 were determined through multiple suspension arrangement array technology. Significant differences were validated by the Kruskal-Wallis and Mann-Whitney U tests. Logistic regression models were performed to assess the association between the IGFBPs and fibrosis stages. The association was determined utilizing odds ratios (ORs), and receiver operating characteristic (ROC) curves were constructed to distinguish the IGFBPs in relation to the diagnosis of fibrosis. IGFBP-1 and IGFBP-7 concentrations were higher in CHC than in the healthy individuals, whereas IGFBP-3, IGFBP-5, and IGFBP-6 were downregulated in the patients. An apparent increase of all the IGFBPs was found at fibrosis stage F4, but with different regulations. IGFBP-2, -4, -6, and -7 had the best OR, showing the relation to fibrosis progression. The ROC curves showed that IGFBP-7 was the only protein that distinguished F1 from F3 and F2 from F3. IGFBPs participate in liver fibrosis progression and could be employed as circulating novel protein panels for diagnosis and as possible therapeutic targets in liver fibrosis progression.

Indexed as

AdultCross-Sectional StudiesFemaleHepatitis C, ChronicHumansInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding Protein 4Insulin-Like Growth Factor Binding Protein 5Insulin-Like Growth Factor Binding Protein 6Insulin-Like Growth Factor Binding ProteinsLiver CirrhosisLogistic ModelsMaleMiddle AgedIGFBP1 protein, humanIGFBP3 protein, humanIGFBP5 protein, humanInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding Protein 4Insulin-Like Growth Factor Binding Protein 5Insulin-Like Growth Factor Binding Protein 6insulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding ProteinsChronic hepatitis CDiagnosticIGFBPsLiver fibrosis

Identifiers

PMID32301061
OpenAlexW3016423438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.